07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

BTL-TML-HSV: Phase I/II data

Pooled data from a double-blind, placebo-controlled, U.S. Phase I/IIa trial and a double-blind, placebo-controlled, U.S. Phase IIb trial in patients who experienced prodromal symptoms of tingling, burning, itching or presence of a lesion following a...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

BTL-TML-HSV: Phase I/IIa data

A double-blind, U.S. Phase I/IIa trial in 31 evaluable patients who experienced prodromal symptoms of tingling, burning, itching or presence of a lesion following a dental procedure showed that sublingual BTL-TML-HSV for 7 days (n=22)...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

Beech Tree preclinical data

In foals challenged with Rhodococcus equi, BTL-slo as an adjunct to clarithromycin and rifampin significantly reduced bacterial counts vs. antibiotics alone (p<0.001). Additionally, BTL-slo plus antibiotics non-significantly improved clinical scores and survival vs. antibiotics alone...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Clinical News

UISH001: Phase I/IIa started

Beech Tree began a double-blind, placebo-controlled, U.S. Phase I/IIa trial to evaluate sublingual thrice-daily UISH001 in 60 patients. Beech Tree Labs Inc. , Providence, R.I.   Product: UISH001   Business: Genitourinary   Molecular target: NA...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Financial News

Beech Tree completes venture financing

Beech Tree Labs Inc. , Providence, R.I.   Business: Infectious, Neurology, Genitourinary   Date completed: 11/16/10   Type: Venture financing   Raised: $7 million   Investors: Private investors  ...
07:00 , Jul 19, 2010 |  BC Week In Review  |  Clinical News

BTL-TML-HSV: Phase I/IIa start

This summer, Beech Tree will begin a placebo-controlled Phase I/IIa trial in 210 patients. Beech Tree Labs Inc. , Providence, R.I.   Product: BTL-TML-HSV   Business: Infectious   Molecular target: NA   Description: Undisclosed small...